ArticleProceedings of the National Academy of Sciences of the United States of America2016
Adenosine A1 receptor antagonist rolofylline alleviates axonopathy caused by human Tau ΔK280.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Microglial purinergic signaling in Alzheimer's disease.Purinergic signalling · 2025Review
- Article
- Apolipoprotein E gene allele 4 and amyloid-beta mediate tau-related network breakdown.Brain communications · 2025Article
- Adenosine deficiency facilitates CA1 synaptic hyperexcitability in the presymptomatic phase of a knock in mouse model of Alzheimer's disease.bioRxiv : the preprint server for biology · 2024Article
- MSUT2 regulates tau spreading via adenosinergic signaling mediated ASAP1 pathway in neurons.Acta neuropathologica · 2024Article
- Critical thinking of Alzheimer's transgenic mouse model: current research and future perspective.Science China. Life sciences · 2023Review
- Spreading of Tau Protein Does Not Depend on Aggregation Propensity.Journal of molecular neuroscience : MN · 2023Article
- Reversal of Tau-Dependent Cognitive Decay by Blocking Adenosine A1 Receptors: Comparison of Transgenic Mouse Models with Different Levels of Tauopathy.International journal of molecular sciences · 2023Article
- Tau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer's disease.Science advances · 2023Article
- Alzheimer's disease: an axonal injury disease?Frontiers in aging neuroscience · 2023Review
- Adenosine receptor signalling in Alzheimer's disease.Purinergic signalling · 2022Review
- Amyloid pathology but not APOE ε4 status is permissive for tau-related hippocampal dysfunction.Brain : a journal of neurology · 2022Article
- Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases.Journal of biomedical science · 2021Review
- PAC1 receptor-mediated clearance of tau in postsynaptic compartments attenuates tau pathology in mouse brain.Science translational medicine · 2021Article
- Inhibition of Tau aggregation with BSc3094 reduces Tau and decreases cognitive deficits in rTg4510 mice.Alzheimer's & dementia (New York, N. Y.) · 2021Article
- Higher CSF Tau Levels Are Related to Hippocampal Hyperactivity and Object Mnemonic Discrimination in Older Adults.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2019Observational
- Propagation of Tau via Extracellular Vesicles.Frontiers in neuroscience · 2019Review
- Adenosine Augmentation Evoked by an ENT1 Inhibitor Improves Memory Impairment and Neuronal Plasticity in the APP/PS1 Mouse Model of Alzheimer's Disease.Molecular neurobiology · 2018Article
- Article
- CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume.Alzheimer's & dementia (Amsterdam, Netherlands) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Accumulation of Tau is a characteristic hallmark of several neurodegenerative diseases but the mode of toxic action of Tau is poorly understood. Here, we show that the Tau protein is toxic due to its aggregation propensity, whereas phosphorylation and/or missorting is not sufficient to cause neuronal dysfunction. Aggregate-prone Tau accumulates, when expressed in vitro at near-endogenous levels, in axons as spindle-shaped grains. These axonal grains contain Tau that is folded in a pathological (MC-1) conformation. Proaggregant Tau induces a reduction of neuronal ATP, concomitant with loss of dendritic spines. Counterintuitively, axonal grains of Tau are not targeted for degradation and do not induce a molecular stress response. Proaggregant Tau causes neuronal and astrocytic hypoactivity and presynaptic dysfunction instead. Here, we show that the adenosine A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.